

CONSUMER PACKAGE INSERT FOR VETERINARY MEDICINAL PRODUCT

The medicine is dispensed with a veterinarian's prescription only
For animal use only

1. NAME AND DOSAGE FORM OF THE VETERINARY MEDICINAL PRODUCT:

Dexafort Veterinary

Suspension for injection

2. COMPOSITION:

Active substances:

Dexamethasone (as phenylpropionate) 2 mg/ml

Dexamethasone (as sodium phosphate) 1 mg/ml

Preservative:

Benzyl alcohol 10.4 mg/ml

For excipients and allergens in the product, see section 13 – “Additional information”.

3. WHAT IS THE MEDICINAL PRODUCT INTENDED FOR:

For the treatment of primary ketosis (acetonemia), in various inflammatory conditions like arthritis and other orthopedic conditions, shock, stress, allergic conditions in horses, cattle, dogs and cats.

Therapeutic group: glucocorticoids

4. CONTRAINDICATIONS:

Do not use in case of sensitivity to the active substance or to any of the excipients listed in section 13.

Except in emergency situations the product should not be used in animals suffering from:

- Diabetes
- Chronic nephritis
- Renal disease
- Congestive heart failure
- Osteoporosis
- Viral infections during the viraemic stage

5. SIDE EFFECTS:

Horses, cattle, dogs and cats:

Very rare (< 1 animal/ 10,000 treated animals,	Polyuria ¹ ; Polydipsia, Polyphagia ¹ ; Other blood disorder ² ;
---	---

including isolated reports)	Cutaneous calcinosis; Delayed healing; Hypersensitivity reaction; Hepatomegaly; Elevated liver enzymes.
-----------------------------	---

¹ Particularly during the early stages of therapy.

² Sodium and water retention and hypokalemia when administered long-term,

If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian.

Reporting side effects

Side effects can be reported to the Ministry of Health by clicking on the link “Reporting Side Effects due to Drug Treatment” found on the Ministry of Health homepage (www.health.gov.il), that directs you to the online form for reporting side effects, or by entering the link:

<https://sideeffects.health.gov.il>

6. TARGET SPECIES:

Horses, cattle, dogs and cats.

7. METHOD OF ADMINISTRATION AND DOSAGE:

Dexafort Veterinary should be administered by intramuscular injection using normal aseptic techniques.

For the treatment of allergic or inflammatory conditions, the following average doses are advised. However, the advised dose used should be determined by the severity of the signs and the length of time for which they have been present.

Species	Dosage
Horses, cattle	1 ml/50 kg
Dog, cat	0.5 ml/10 kg

For the treatment of primary ketosis in cattle (acetoanaemia)

A dose of 5-10 ml, dependent on the size of the cow. Since blood sugar levels rise rapidly following injection of the product, through the action of dexamethasone sodium phosphate and raised levels are maintained for several days, the product is particularly useful in cases that present late and there is seldom a need to repeat the dose.

In the case of cows in poor bodily condition, to avoid prolonged stimulation of gluconeogenesis at the expense of body fat reserves, use a product containing only the quick-acting ester.

8. HOW TO USE THE PRODUCT:

Before use shake vial upright thoroughly for 30 seconds.

Dexafort Veterinary should be administered by intramuscular injection, using normal aseptic techniques, by use of a minimum 21 G cannula.

To measure small volumes of less than 1 ml, a suitably graduated syringe should be used to ensure accurate administration of the correct dose.

9. WITHDRAWAL PERIOD:

Cattle: meat - 63 days

milk - 7 days

10. WARNINGS:

Special warnings

Care should be taken when the product is used for the treatment of laminitis in horses, where there is a possibility that such treatment could worsen the condition.

The use of the product in horses for other conditions could induce laminitis and careful observations during the treatment period should be made.

Special warnings for safe use in the target species

Anti-inflammatory corticosteroids, such as dexamethasone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control clinical signs.

During a course of treatment the situation should be reviewed frequently by close veterinary supervision.

Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g., redistribution of body fat, muscle weakness and wastage and osteoporosis may result.

During therapy effective doses suppress the hypothalamo-pituitary-adrenal axis. Following cessation of treatment, symptoms of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, e.g., dosing to coincide with the time of the endogenous cortisol peak (i.e., in the morning with regard to dogs and the evening for cats) and a gradual reduction of dosage (for further discussion see standard texts).

Corticosteroids may delay wound healing and the immunosuppressive effect can weaken the immune system or worsen pre-existing infections. In the presence of bacterial infection, antibacterial drug cover is usually required when steroids are used. In the presence of viral infections, steroids may worsen or hasten the progress of the disease.

Systemic corticosteroid therapy is generally contraindicated in patients with renal disease and diabetes mellitus. Gastrointestinal ulceration has been reported in animals treated with corticosteroids and gastrointestinal ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in animals with spinal cord trauma.

Special warnings relating to the safety of the person administering the medicinal product to animals

The veterinary medicinal product can cause allergic reactions. People with known hypersensitivity to the active substance or to any of the excipients should avoid contact with the veterinary medicinal product.

Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.

To avoid the risk of self-injection, pregnant women should not handle the veterinary medicinal product.

Avoid contact with skin and eyes. In the event of accidental eye or skin contact, wash the area with clean running water. Seek medical attention if irritation persists. Wash hands after use.

Pregnancy and lactation in treated animal

Corticosteroids are not recommended for use in pregnant animals. Administration in early pregnancy is known to have caused foetal abnormalities in laboratory animals. Administration at late pregnancy may cause early parturition or abortion.

Use of the product in lactating cows may cause a reduction in milk yield.

Interactions with other medicinal products and other types of interactions

Refer to section "Special precautions for safe use in the target species".

Overdose

Refer to section "Side effects".

Major Incompatibility

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

11. STORAGE INSTRUCTIONS:

- Avoid poisoning! This medicinal product and any other medicinal products, should be kept in a safe place, out of the reach and sight of children and/or infants in

order to protect from poisoning.

- Do not use the medicinal product after the expiry date (exp. Date) appearing on the package. The expiry date refers to the last day of that month.
- Storage conditions:
Store below 25°C.
Keep the vial in the outer carton in order to protect from light.
Store the product in upright position.
Discard unused material.
- Shelf life after first opening: 28 days.

12. INSTRUCTIONS REGARDING DISPOSAL OF THE MEDICINAL PRODUCT/REMNANTS OF THE MEDICINAL PRODUCT AFTER USE:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of as toxic waste, do not throw to sewer.

13. ADDITIONAL INFORMATION:

- In addition to the active substance, the medicine also contains:
Sodium citrate dihydrate, Benzyl alcohol, Sodium chloride, Tragacanth, Methylcellulose, Sodium hydroxide 1N, Hydrochloric acid 1N, Water for injection.
- What the medicine looks like and the content of the package:
A white to off-white suspension.
The package: A glass vial of 50 ml, closed with a rubber stopper (butyl) and aluminum overseal, with a blue flip-off cap.
- Manufacturer name and address:
Intervet International B.V. (MSD Animal Health), Boxmeer, Netherlands.
- Registration holder and address: Intervet Israel Ltd., Industrial Park Neve Ne'eman, Hod Hasharon 45240.

Revised in January 2026.

Registration number of the medicinal product in the National Drug Registry of the Ministry of Health: 082-08-91518-00